Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop
© Öhlund et al.; licensee BioMed Central Ltd. 2013
Received: 18 September 2012
Accepted: 19 March 2013
Published: 26 March 2013
Pancreatic cancer shows a highly aggressive and infiltrative growth pattern and is characterized by an abundant tumor stroma known to interact with the cancer cells, and to influence tumor growth and drug resistance. Cancer cells actively take part in the production of extracellular matrix proteins, which then become deposited into the tumor stroma. Type IV collagen, an important component of the basement membrane, is highly expressed by pancreatic cancer cells both in vivo and in vitro. In this study, the cellular effects of type IV collagen produced by the cancer cells were characterized.
The expression of type IV collagen and its integrin receptors were examined in vivo in human pancreatic cancer tissue. The cellular effects of type IV collagen were studied in pancreatic cancer cell lines by reducing type IV collagen expression through RNA interference and by functional receptor blocking of integrins and their binding-sites on the type IV collagen molecule.
We show that type IV collagen is expressed close to the cancer cells in vivo, forming basement membrane like structures on the cancer cell surface that colocalize with the integrin receptors. Furthermore, the interaction between type IV collagen produced by the cancer cell, and integrins on the surface of the cancer cells, are important for continuous cancer cell growth, maintenance of a migratory phenotype, and for avoiding apoptosis.
We show that type IV collagen provides essential cell survival signals to the pancreatic cancer cells through an autocrine loop.
KeywordsType IV collagen Pancreatic cancer Basement membrane Integrin receptors Autocrine loop
Pancreatic cancer is a disease with extremely poor prognosis. The five-year survival rate has only improved marginally over the past decades, and remains at less than 5% [1, 2]. Consequently, pancreatic cancer has the lowest long-term survival rate among the common malignancies. The disease typically displays an aggressive, rapid and infiltrative growth pattern, with metastases often already seeded at the time of diagnosis.
Pancreatic cancer is characterized by an abundant fibrotic tumor stroma, referred to as the desmoplastic reaction, which surrounds and infiltrates clusters of cancer cells. Approximately 80% of the tumor mass is made up by the tumor stroma, which is composed of connective tissue, predominantly type I and type III collagen , but also a variety of other extracellular matrix (ECM) proteins, blood vessels, inflammatory cells, and activated pancreatic stellate cells (PSC).
In most situations the PSC is a quiescent fat storing cell, but after activation morphological changes occur and it becomes a highly active matrix-producing myofibroblast-like cell, expressing large amounts of type I collagen and fibronectin . Pancreatic cancer cells have been shown to activate the PSC by paracrine mechanisms involving transforming growth factor-β (TGF-β) . The activated PSC is the main producer of the stromal ECM, thus, creating a tumor-supportive microenvironment, resulting in increased tumor growth .
The desmoplastic reaction is also believed to be important for the pronounced drug resistance seen in pancreatic cancer. Pancreatic cancer cells attached to type I collagen display increased survival when treated with 5-FU , and interactions with other ECM molecules, such as type IV collagen, fibronectin, or laminin, also result in decreased cytotoxicity of anticancer drugs . Furthermore, in a mouse model of pancreatic cancer, inhibition of the Hedgehog signaling pathway led to a depletion of the desmoplastic reaction, and subsequently a better response to chemotherapy .
Type IV collagen is upregulated in the tumor stroma and found in discontinuous basement membranes (BM) [9, 10]. We have previously shown that type IV collagen is highly expressed in close proximity to the pancreatic cancer cells in vivo. Type IV collagen is the main component of the BM and provides a scaffold for assembly and mechanical stability, but is also important in cell adhesion, migration, survival, proliferation, and differentiation . Not only is the activated PSC involved in the production of the stromal ECM, but the cancer cells also produce stromal components both in vivo and in vitro. It has been shown that many pancreatic cancer cell lines and xenografted human pancreatic tumors express ECM proteins both at the RNA and protein level, and most interestingly, type IV collagen synthesis exceeds that of all other ECM proteins examined, including that of type I collagen .
Integrin receptors are transmembrane glycoproteins that are the major cell surface receptors for the ECM, consisting of one α and one β subunit. Both α1β1 and α2β1 bind type IV and type I collagens, though α1β1 has a higher affinity for type IV collagen and α2β1 for type I collagen . Integrin receptors known to bind type IV collagen (α2β1 and α1β1) are highly expressed by pancreatic cancer cells . Furthermore, they are also expressed over the entire cancer cell, not only at the basolateral side as in normal pancreatic tissue . Inhibition of integrin β1 has been shown to suppress invasion of pancreatic cancer cells in vitro. The integrins have multiple binding-sites on the type IV collagen molecule, but the major binding-site for both α1β1 and α2β1 integrins has been identified within the collagenous domain of type IV collagen and is referred to as the CB3-region. By using antibodies to block the CB3 region, 80% of cell adhesion to type IV collagen was inhibited on a variety of carcinoma cell lines .
In this study we examine the role of cancer cell-derived type IV collagen and its effects on cancer growth, apoptosis, and migration, and provide evidence of type IV collagen as an important autocrine factor for cancer cell proliferation, survival, and migration in pancreatic cancer.
Tissue samples of pancreatic ductal adenocarcinomas were collected from patients undergoing a curatively aimed pancreatico-duodenectomy at the Department of Surgery at Umeå University Hospital (n = 9). Normal pancreatic tissue samples were collected from patients who underwent surgery in organs close to the pancreas, but where the disease did not involve the pancreas (n = 7). Samples were snap frozen in liquid nitrogen and stored at -80°C until analysis. This study is approved by the Research Ethics Review Board (EPN) of Northern Sweden.
Cell lines and cell culturing
Two well-characterized human pancreatic adenocarcinoma cell lines were used. HPAC (ATCC, CRL-2119), a human pancreatic adenocarcinoma cell line of ductal origin, is derived from a moderate to well differentiated pancreatic adenocarcinoma . CFPAC-1 (ATCC, CRL- 1918) was derived from a patient with a ductal adenocarcinoma . HPAC was cultured with 1:1 mixture of Dulbecco’s modified Eagle’s and Ham’s F12 medium (DMEM/F12), CFPAC-1 with 90% Iscove’s modified Dulbecco’s medium (IMDM), both supplemented with 10% fetal calf serum (FCS), penicillin (105 IU/L), and streptomycin (100 mg/L) and grown in an incubator at 37°C in an atmosphere with 5% CO2.
Cell and tissue staining
Immunofluorescence stainings were performed on 6 μm frozen sections, and on cells cultured on Falcon™ Culture Slides (BD Biosciences, Erembodegem, Belgium) using methods previously described , with the following primary antibodies and dilutions: mouse anti-human integrin α1 (MAB1973, 1:40); mouse anti-human integrin α2 (MAB1950, 1:40); mouse anti-human integrin β1 (MAB1959, 1:500), all from Millipore (Billerica, MA, USA); and rabbit anti-human type IV collagen (MP Biomedicals, LLC, Solon, OH, USA; cat. no. 10760, 1:100); goat anti-human type XVIII collagen (R&D Systems, Minneapolis, MN, USA; AF570, 1:75), goat anti-human perlecan (R&D Systems, Minneapolis, MN, USA; AF2364, 1:75), rat anti-human laminin-γ1 (Millipore, Billerica, MA, USA, Mab1914P, 1:75), rabbit anti-human nidogen (Millipore, Billerica, MA, USA, cat. no. 481978, 1:75), mouse anti-human cytokeratin 18 (DakoCytomation, Glostrup, Denmark, DC10 1:100) and sheep anti-CD31 (R&D Systems, Inc., Minneapolis, MN, USA; AF806, 1:50). Cultured cells were stained with the integrin antibodies mentioned above together with the goat anti-type IV collagen antibody (Chemicon, Billerica, MA, USA; AB769, 1:50). Double staining on tissue for type I and type IV collagen was performed with a rabbit anti-human type I collagen antibody (Cedarlane Laboratories, Burlington, NC, USA; CL50111AP, 1:200) and a mouse anti-α1(IV)NC1 (Wieslab, Malmö, Sweden; MAB1, 1:75) . Secondary antibodies used were: donkey anti-rabbit FITC, donkey anti-mouse TRITC and FITC, donkey anti-goat TRITC (all Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA; with dilutions 1:100). Sections were mounted with medium containing DAPI (Vectashield, Vector Laboratories, Inc., Burlingame, CA, USA). Negative control sections were incubated with secondary antibodies only. Hematoxylin and eosin (H&E) stainings were performed according to standard protocols.
Migration, proliferation, and apoptosis assays
Cell proliferation was measured using CellTiter-Glo® (Promega Corporation, Madison, WI, USA), a luminescence based cell viability assay, and cell apoptosis was assayed with the M30-Apoptosense® ELISA (Peviva AB, Bromma, Sweden). In the apoptosis assay the apoptosis-associated caspase-cleaved cytokeratin 18 is quantitatively determined, and high concentrations of the M30 neo-epitope indicate high apoptotic activity. Both assays were performed according to the manufacturers’ instructions. For both assays, 5–6 × 103 cells were seeded in triplicates on 96-well polystyrene plates, culture area 0.34 cm2/well (Nunc, Roskilde, Denmark), with coated or uncoated surfaces. Proliferation and apoptosis was measured after 2–3 days incubation, and the cells were ensured to be in growth phase when assayed (data not shown). For the apoptosis assay, the triplicates were pooled together and run in duplicates. Furthermore, the fraction of cells in S-phase was measured with flow cytometry, and cells were stained and analyzed according to standard techniques previously described . Transfected cells and control cells were solved in PBS and run in triplicates. DNA histograms were evaluated for ploidy (ModFit LT 3.0™, Verity Software House, Topsham, ME, USA) in order to identify the fraction of cells in the S-phase.
For the matrix studies, type IV and type I collagen (BD Biosciences, Two Oak Park, Bedford, MA, USA) and Bovine Serum Albumin (BSA, used as unspecific control protein) were coated to the wells. For the blocking studies, wells were coated with antibodies directed against the NC1, CB3, and 7S domains of the type IV collagen. These antibodies were: mouse-anti-α1(IV)NC1 (Wieslab, Malmö, Sweden, MAB1); mouse-anti-α2(IV)7S (Chemicon International, Inc., Billerica, MA, USA; MAB1910); mouse anti-human collagen type IV antibody (Acris Antibodies GmbH, Herford, Germany; clone CIV22) ; and whole mouse IgG (used as control, Jackson ImmunoResearch Laboratories, Inc.). The coated proteins were diluted in 2 mM hydrochloric acid or 10 mM acetic acid, followed by incubation for 2 hours in the wells. The wells were then washed, cells added, and grown under FCS free conditions.
For the integrin blocking studies, cells were grown in FCS supplemented medium for one day, washed and thereafter, the blocking antibody diluted in serum free medium was added. Antibodies known to functionally block the integrin receptors and a control IgG antibody were used (all mentioned above).
Migration was studied in a wound-healing assay, in which cells were grown on a 24-well wound healing assay plate (Cell Biolabs, Inc., San Diego, CA, USA), and standardized wounds (0.9 mm) were generated according to the manufacturer’s instructions. Two or more wells were used for each experiment, and pictures were taken every 10 minutes (Olympus IX81 with Cell-R software) with time-lapse Differential Interference Contrast microscopy (DIC), and the time of wound closure was determined at two different locations for each wound. Cells were grown under FCS supplemented conditions.
CFPAC-1 cells were transfected with a pool of 3 different target-specific siRNAs designed to knock down the gene expression of the COL4A1 gene, and control the siRNA design to not target any known human gene (Santa Cruz Biotechnology, Inc., CA, USA, sc-43064 and sc-37007). Subsequently, 5 x 104 cells/ml were seeded in 6 well plates (Nunc, Roskilde, Denmark), and transfected according to the manufacturer’s protocol. The down-regulation of type IV collagen synthesis was verified by quantitative real time-PCR. Approximately 2x105 cells from each cell culture were harvested by centrifugation, and the total RNA was extracted using the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). Equal amounts (1 μg) of RNA were reverse transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen). Gene expression was quantified using the Bio-Rad iQ SYBR Green Supermix and the iQ5 iCycler according to the manufacturer’s instructions. The primer set 5′-TGCACCACCAACTGCTTAGC-3′ and 5′-GGCATGGACTGTGGTCATGAG-3′ for the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) housekeeping gene was used for normalization, and the primer set 5′-CTCTACGTGCAAGGCAATGA-3′ and 5′-AGAACAGGAAGGGCATTGTG-3′, designed using the web-based PCR primer design tool Primer3 (Rozen and Skaletsky, 2000) was used for quantification of the COL4A1 gene. All reactions were run at 95°C for 3 minutes, followed by 40 cycles at 95°C for 10 seconds and at 60°C for 30 seconds.
Additionally, the type IV collagen protein expression was detected in the transfected cells using immunofluorescence staining with the MAB1 antibody. The transfected cells were assayed for proliferation, apoptosis, and migration as described above. For the cell proliferation assay, the experiments were repeated five times with similar results both under FCS free and serum supplemented conditions.
All assays performed on 96-well plates were run in triplets. For the M30-Apoptosense® ELISA, the triplicates were subsequently pooled and the final analysis was performed on duplicates of the pooled samples. Normal distribution was assumed. Unpaired t-test was used when comparing two groups and ANOVA with Bonferroni post-hoc test if more than two groups were compared. P < 0.05 was considered significant. Bars in the figures illustrate the standard deviation.
Type IV collagen is highly expressed in the stroma of pancreatic cancer when compared to other basement membrane proteins
The expression of type IV collagen and other BM proteins (type XVIII collagen, laminin, nidogen and perlecan) was studied by immunofluorescence in normal pancreas and pancreatic cancer tissue. In normal tissue all these BM proteins have the same expression pattern with expression in the epithelial and vascular BM (Additional file 1: Figure S1). However, in cancer distinctly different expression patterns were observed, with high expression of type IV collagen in vicinity of the cancer cells. Perlecan and nidogen expression was also observed in the stroma, although the staining pattern and intensity was lower than that observed for type IV collagen. For type XVIII collagen and laminin only little expression was observed in the tumor stroma (Additional file 1: Figure S1).
Type IV collagen is highly expressed in close proximity to the pancreatic cancer cells and colocalizes with integrin α1, α2, and β1on the cancer cell surface
Both type I and type IV collagens promote growth and migration and inhibit apoptosis, but are expressed in different stromal compartments
Pancreatic cancer cells were grown on both type I or type IV collagen matrices, and both types of collagen promote cell growth when compared to a control protein matrix (Figure 4B). Furthermore, there was a tendency of having reduced induction of apoptosis when the pancreatic cancer cells were grown on collagen matrices (Figure 4C). Migration was measured in a wound-healing assay, in which cells were grown on the different collagens and the time of wound closure was compared to cells grown on a control matrix (Figure 4D). The wounds of cells grown on a collagen matrix closed faster than wounds grown on the control matrix, indicating that cells in contact with type I or type IV collagens develop a more migratory phenotype.
Type IV collagen is an important autocrine factor regulating growth and migration in pancreas cancer cells
By blocking the integrin receptors α1, α2, and β1 a decrease in cell growth was observed (Figure 5A). For integrin α1 and β1 this growth inhibition was dose dependent.
The integrin receptors predominantly bind to the CB3 region of the type IV collagen molecule, but also to the NC1 domain . By blocking these binding sites with region-specific antibodies, a decrease in cell growth was seen when blocking the CB3 region, but not when blocking the NC1 domain (Figure 5B). The 7S domain is not known to bind to any integrins; hence, blocking this domain did not affect cancer cell growth.
Additional file 5: Movie S1: Difference in migration for α1- and control-transfected cells. Movie that illustrates the difference in migratory capacity between α1(IV)-siRNA transfected and control-siRNA transfected cells. (MOV 6 MB)
Furthermore, the reduction of cell growth induced by down-regulation of α1(IV) synthesis was normalized when the cells were grown on a type IV collagen matrix (Figure 5D). This growth rescue effect was not achieved if the cells were grown on a control matrix composed of BSA. Moreover, the rescue once again failed if integrin β1 receptors were blocked during the time the α1(IV)-siRNA transfected cells were grown at the type IV collagen matrix (Figure 5D).
Together, these data demonstrate the importance of type IV collagen/integrin receptor interactions and shows that type IV collagen is an important autocrine factor, regulating growth, migration, and apoptosis in pancreas cancer cells.
Previous studies have shown that many integrin receptors are expressed in pancreatic cancer cells [14, 16]. Type IV collagen is produced by the cancer cells, and is deposited in direct proximity to the cancer cells in the pancreatic tumor stroma, forming discontinuous BM like structures [9–11], but the functional role of this is unknown. This is not the case for all BM proteins as shown in this study, which indicates that these proteins although expressed in the same structure in normal pancreas tissue, can have different functions in pancreatic cancer. Cancer is a clonal disease and the cancer cells seen in an advanced cancer are all results of many cell generations of active selection, where the cells most fitted for rapid expansion have gained a growth advantage. Protein synthesis is an energy consuming process for all cells, and if type IV collagen synthesis was not of importance for cancer progression, clones with lower collagen production would have emerged and gained advantage in the cancer cell population. Thus, the observed accumulation of BM like structures close to the cancer cells both in vivo and in vitro must mean that type IV collagen is, somehow, important for the cancer cells. In this study we show that type IV collagen colocalizes with integrins known to bind type IV collagen on the cancer cell surface both in vivo and in vitro, and that the interaction between the CB3 region of the type IV collagen molecule, and integrin receptors (especially β1) on the surface of the cancer cells, is an important factor that stimulates proliferation and migration, and inhibits apoptosis in pancreatic cancer cells. This finding also gives a rationale for the abundant deposition of type IV collagen seen in human pancreatic cancer tissue.
Furthermore, we show that type I collagen also promotes cancer cell proliferation, migration, and regulates apoptosis, in the same extent as type IV collagen, but that these two collagen types are expressed in different compartments of the tumor stroma in vivo. The PSC are located in the desmoplastic area and are the main producers of type I collagen in the stroma, but most cancer cells are not in direct contact with type I collagen, whereas type IV collagen is produced by the cancer cells themselves, and forms BM like structures surrounding clusters of cancer cells. Taken together, although it is likely that both type I and type IV collagens are important for pancreatic cancer progression, they might have distinct roles in the pathogenesis of pancreatic cancer.
The integrin-ECM axis in pancreatic cancer is believed to play an important role in regulating growth and migration of pancreatic cancer cells . Mutations in pancreatic cancer cells lead to constitutive activation of TGF-β1, which in turn results in the proliferation of pancreatic stellate cells (PSC) . PSCs produce the type I collagen and fibronectin found in the desmoplasia, which in turn mediates cancer cell proliferation and migration through integrin receptors (α2β1 for type I collagen and α5β1 for fibronectin). In addition to this paracrine mechanism, based on our findings, we provide evidence of an autocrine loop of endogenous type IV collagen produced by the pancreatic cancer cell, important in regulating growth, apoptosis, and migration in pancreatic cancer. We hypothesize that pancreatic cancer cells, by producing BM proteins such as type IV collagen, form their own BM-like structures that the cancer cells, in an autocrine manner, can anchor to and consequently, achieve sustained cell growth, avoid apoptosis, and develop a migratory phenotype.
Our data show that reduced production of endogenous type IV collagen, blocking of the CB3-region on the type IV collagen molecule and blocking of the integrin β1 receptor, all lead to a pronounced growth inhibition. However, the antibody we used to block the CB3-region has been shown not to affect the binding of integrin α1β1 to type IV collagen . As expression of integrin α1 in vivo was only occasionally observed on pancreatic cancer cells, and was found mostly intracellular in vitro, our results indicate that integrin α1 is of less importance for the interaction we have studied, and that integrin β1 in combination with another α subunit, forming dimers with affinity to the CB3-region, causes the observed effects.
Attachment to the BM is crucial for the survival and growth of the epithelial cells. Integrin receptors play an important role in anchoring the cells and in providing survival signals, and if the epithelial cell loses contact with the BM, apoptosis is initiated [24, 25]. Pancreatic adenocarcinoma is of epithelial origin, and in the transformation process this mechanism must be overrun; otherwise, apoptosis will be induced as soon as the BM is degraded in order to make subsequent tumor growth possible. We believe that pancreatic cancer cells, by producing their own BM, gain proliferative and invasive properties of crucial importance for the pathogenesis of pancreatic cancer. We have studied type IV collagen, one of the most abundant components of all BM and highly expressed by pancreatic cancer cells [9, 10, 13]. Most certainly other BM proteins are produced and show similar autocrine effects, and we show here that proteins such as nidogen and perlecan are also found in the tumor stroma. Therefore, the tumor produced BM might conceal future therapeutic targets that will be important for the development of new treatment strategies for pancreatic cancer.
In this study we demonstrate that type IV collagen is produced by the pancreatic cancer cells and forms BM like structures surrounding the cancer cells. Through an autocrine loop, type IV collagen interacts with integrin receptors on the surface on the cancer cells, and stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis.
Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Activated pancreatic stellate cell
Transforming growth factor-β.
This work was supported by the Swedish Cancer Society (MS), the Swedish Research Council, grant 2011-3089 (MS), Västerbotten County Council (VLL) (MS, DÖ), the J.C. Kempe Memorial Foundation Scholarship Fund (DÖ), Cancerforskningsfonden Norrland (MS), the Young Researcher Award of Umeå University (MS) and Insamlingsstiftelsen för Medicinsk Forskning vid Umeå universitet (MS). We thank Anette Berglund for skillful technical assistance with sectioning and staining procedures, and Kent Persson (Department of Clinical Pathology, University Hospital of Umeå) for performing the flow cytometry experiments.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.View ArticlePubMedGoogle Scholar
- Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS: Validation of the 6th edition AJCC pancreatic cancer staging system: report from the national cancer database. Cancer. 2007, 110: 738-744. 10.1002/cncr.22852.View ArticlePubMedGoogle Scholar
- Goldstein D, Carroll S, Apte M, Keogh G: Modern management of pancreatic carcinoma. Intern Med J. 2004, 34: 475-481. 10.1111/j.1444-0903.2004.00658.x.View ArticlePubMedGoogle Scholar
- Bachem MG, Zhou S, Buck K, Schneiderhan W, Siech M: Pancreatic stellate cells–role in pancreas cancer. Langenbecks Arch Surg. 2008, 393: 891-900. 10.1007/s00423-008-0279-5.View ArticlePubMedGoogle Scholar
- Omary MB, Lugea A, Lowe AW, Pandol SJ: The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest. 2007, 117: 50-59. 10.1172/JCI30082.View ArticlePubMedPubMed CentralGoogle Scholar
- Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, Johnson CD, Benyon RC, Iredale JP: Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004, 10: 7427-7437. 10.1158/1078-0432.CCR-03-0825.View ArticlePubMedGoogle Scholar
- Grzesiak JJ, Ho JC, Moossa AR, Bouvet M: The integrin-extracellular matrix axis in pancreatic cancer. Pancreas. 2007, 35: 293-301. 10.1097/mpa.0b013e31811f4526.View ArticlePubMedGoogle Scholar
- Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009, 324: 1457-1461. 10.1126/science.1171362.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee CS, Montebello J, Georgiou T, Rode J: Distribution of type IV collagen in pancreatic adenocarcinoma and chronic pancreatitis. Int J Exp Pathol. 1994, 75: 79-83.PubMedPubMed CentralGoogle Scholar
- Linder S, Castanos-Velez E, von Rosen A, Biberfeld P: Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. Hepatogastroenterology. 2001, 48: 1321-1327.PubMedGoogle Scholar
- Ohlund D, Lundin C, Ardnor B, Oman M, Naredi P, Sund M: Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer. 2009, 101: 91-97. 10.1038/sj.bjc.6605107.View ArticlePubMedPubMed CentralGoogle Scholar
- Khoshnoodi J, Pedchenko V, Hudson BG: Mammalian collagen IV. Microsc Res Tech. 2008, 71: 357-370. 10.1002/jemt.20564.View ArticlePubMedPubMed CentralGoogle Scholar
- Lohr M, Trautmann B, Gottler M, Peters S, Zauner I, Maillet B, Kloppel G: Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins. Br J Cancer. 1994, 69: 144-151. 10.1038/bjc.1994.24.View ArticlePubMedPubMed CentralGoogle Scholar
- Grzesiak JJ, Bouvet M: Determination of the ligand-binding specificities of the alpha2beta1 and alpha1beta1 integrins in a novel 3-dimensional in vitro model of pancreatic cancer. Pancreas. 2007, 34: 220-228. 10.1097/01.mpa.0000250129.64650.f6.View ArticlePubMedGoogle Scholar
- Lohr M, Trautmann B, Gottler M, Peters S, Zauner I, Maier A, Kloppel G, Liebe S, Kreuser ED: Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas. Pancreas. 1996, 12: 248-259. 10.1097/00006676-199604000-00007.View ArticlePubMedGoogle Scholar
- Sawai H, Okada Y, Funahashi H, Takahashi H, Matsuo Y, Yasuda A, Ochi N, Takeyama H, Manabe T: Basement membrane proteins play an important role in the invasive processes of human pancreatic cancer cells. J Surg Res. 2008, 144: 117-123. 10.1016/j.jss.2007.03.023.View ArticlePubMedGoogle Scholar
- Vandenberg P, Kern A, Ries A, Luckenbill-Edds L, Mann K, Kuhn K: Characterization of a type IV collagen major cell binding site with affinity to the alpha 1 beta 1 and the alpha 2 beta 1 integrins. J Cell Biol. 1991, 113: 1475-1483. 10.1083/jcb.113.6.1475.View ArticlePubMedGoogle Scholar
- Gower WJ: HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Dev Biol. 1994, 30A: 151-161.View ArticleGoogle Scholar
- Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT, Kelly DR, Schmid SM, Gelder FB, Rado TA: A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci USA. 1990, 87: 4012-4016. 10.1073/pnas.87.10.4012.View ArticlePubMedPubMed CentralGoogle Scholar
- Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R: Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell. 2003, 3: 589-601. 10.1016/S1535-6108(03)00133-8.View ArticlePubMedPubMed CentralGoogle Scholar
- Johansson C, Butkowski R, Wieslander J: Characterization of monoclonal antibodies to the globular domain of collagen IV. Connect Tissue Res. 1991, 25: 229-241. 10.3109/03008209109029159.View ArticlePubMedGoogle Scholar
- Vindelov LL, Christensen IJ, Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983, 3: 323-327. 10.1002/cyto.990030503.View ArticlePubMedGoogle Scholar
- Eble JA, Golbik R, Mann K, Kuhn K: The alpha 1 beta 1 integrin recognition site of the basement membrane collagen molecule [alpha 1(IV)]2 alpha 2(IV). EMBO J. 1993, 12: 4795-4802.PubMedPubMed CentralGoogle Scholar
- Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell. 2002, 110: 673-687. 10.1016/S0092-8674(02)00971-6.View ArticlePubMedGoogle Scholar
- Huveneers S, Truong H, Danen HJ: Integrins: signaling, disease, and therapy. Int J Radiat Biol. 2007, 83: 743-751. 10.1080/09553000701481808.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/154/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.